Monoclonal Antibodies Market Analysis

Monoclonal Antibodies Market Analysis

To get key market trends

  Download Free Sample

Based on type, the monoclonal antibodies market is classified into fully human, humanized, chimeric, and other types. Fully human monoclonal antibodies segment dominated the monoclonal antibodies industry with 50.8% market share in 2022. Increase in number of product approvals and drug launches of fully human monoclonal antibodies has positively impacted the segment gains by 2032. Integration of advanced technologies has enabled faster discovery and product development. The large-scale production of fully human monoclonal antibodies is cost-effective and more feasible due to the advances in biotechnology and cell culture techniques. This will further lead to shift in focus towards the use of fully human mAbs for immunotherapeutic applications. The use of fully human monoclonal antibodies reduces the risk of cross-reactivity with antigens in non-human species, while studying disease in animal models.
 

Based on application, the monoclonal antibodies market is classified oncology, autoimmune diseases, infectious diseases, and other applications. Oncology segment is anticipated to proceed at 12.6% CAGR by 2032. Monoclonal antibodies are proven effective for targeted treatment of cancer. Moreover, numerous monoclonal antibodies have multiple applications offering advantage of single mAb to target different types of cancers. Moreover, to cater increasing disease burden, key market players are adopting developmental activities.
 

Based on end-use, the monoclonal antibodies market based on end-use is segmented as hospitals, specialty centres, and other end-uses. Hospitals segment was valued around USD 79.6 billion in 2022 owing to increase in number of patient hospitalizations for range of chronic diseases. Hospitals are well-equipped to manage chronic diseases and other complex medical conditions, and the availability of advanced drug therapies in hospitals has driven patient preference. Highly skilled professionals providing specialty treatments such as cancer and autoimmune diseases drives the product demand in hospitals. Moreover, reimbursement policies for high-cost therapies in hospitals influence the patient visits.
 

North America monoclonal antibodies market accounted for more than 48.8% in 2022 owing to the strong presence of key business players and number of product approvals. Enhanced product adoption for effective disease treatment propels demand for monoclonal antibodies in the regional business. Moreover, increasing R&D expenditure by organizations and support for cancer research by the government has allowed discovery of novel monoclonal antibodies therapeutics. Additionally, expansion of manufacturing capacities boosts product availability and sales. Moreover, increasing number of product approvals in the U.S. and Canada stimulates the regional industry progression. Well-developed healthcare infrastructure has increased treatment accessibility to population.